Ignis Therapeutics, a central nervous system (CNS)-focused biotech firm set up by SK Biopharmaceuticals in China, has raised $180 million in a Series A round of financing to bring the South Korean drug developer’s products to the world’s second-largest pharmaceutical market.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $52.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at firstname.lastname@example.org